Skip to main content

Table 2 Biopsy findings and biochemical parameters in proliferative and non-proliferative glomerulonephritis patients after division into Responders and Non-Responders subgroups (mean ± SD)

From: Macrophage migration inhibitory factor urinary excretion revisited – MIF a potent predictor of the immunosuppressive treatment outcomes in patients with proliferative primary glomerulonephritis

 

Proliferative GN

Non-proliferative GN

Responders (R)

Non-Responders (NR)

Responders (R)

Non-Responders (NR)

Patients (n)

31

20

22

11

Uncontrolled hypertension (n)

3

2

2

2

ACE-I or ARB treatment(n)

29

18

21

11

Interstitium volume (%) ± SD

30.3 ± 2.27b,c

31.1 ± 3.11d,e

14.2 ± 5.47b,d

15.03 ± 7.35c,e

Median

22.3

21.5

16.7

18.3

Glomerulosclerosis (grade) ± SD

1.65 ± 0.81

1.68 ± 0.74

2.66 ± 0.51

2.59 ± 0.61

Median

1.88

1.99

2.24

2.15

Mesangial cellularity

1.45 ± 0.28

1.39 ± 0.19

0.96 ± 0.11

0.87 ± 0.19

Median

1.22

1.19

0.99

0.91

Serum creatinine before treatment (mg %) ± SD

1.88 ± 1.01

1.86 ± 1.1

1.45 ± 1.19

1.66 ± 1.4

Median

1.75

1.73

1.59

1.61

Serum creatinine after treatment (mg %) ± SD

1.40 ± 1.42a,c

2.17 ± 1.61

1.23 ± 1.14d,f

2.39 ± 1.74

Median

1.39

1.93

1.24

2.27

LDL before treatment (mg/dl) ± SD

126 ± 41.1a,b,c

139 ± 39.7

145.7 ± 39.1

146.8 ± 41.7

Median

122.2

137.5

141.7

142.6

LDL after treatment (mg/dl) ± SD

87.9 ± 10.4

88.8 ± 11.1

88.1 ± 9.9

89.5 ± 11.6

Median

86.6

87.9

88.0

88.4

Total serum proteins before treatment (g/dl) ± SD

6.02 ± 0.55

6.11 ± 0.58

5.51 ± 1.82

5.48 ± 1.78

Median

5.88

5.91

5.55

5.69

Total serum proteins after treatment (g/dl) ± SD

6.42 ± 0.62a,c

5.64 ± 0.81a,d

6.65 ± 0.6d,f

5.24 ± 0.89c,f

Median

6.56

5.54

6.74

5.31

Proteins urine excretion before treatment (mg/mg Cr) ± SD

11.4 ± 2.44b,c

12.1 ± 6.08d,e

61.25 ± 9.4b,d

58.90 ± 88.18c,e

Median

10.5

11.0

58.5

51.3

Proteins urine excretion after treatment (mg/mg Cr) ± SD

1.58 ± 3.1a,b,c

2.96 ± 9.14a,e

5.55 ± 2.25b,f

19.9 ± 14.3b,c,e,f

Median

1.31

2.66

3.88

16.74

  1. Differences were considered significant for P < 0.05 (Kruskal-Wallis ANOVA)
  2. aProliferative GN R versus NR
  3. bProliferative GN R versus non-proliferative GN R
  4. cProliferative GN R versus non-proliferative GN NR
  5. dProliferative GN NR versus non-proliferative GN R
  6. eProliferative GN NR versus non-proliferative GN NR
  7. fNon-proliferative GN R versus NR